首页 | 官方网站   微博 | 高级检索  
相似文献
 共查询到18条相似文献,搜索用时 171 毫秒
1.
目的 观察环氧合酶2(COX-2)对人胃癌裸鼠移植瘤的影响并探讨其机制.方法 构建靶向COX-2表达质粒和在BALB/c裸鼠皮下建立SGC-7901人胃癌细胞动物模型,用COX-2表达质粒基因转染治疗.结果 构建的COX-2表达质粒在体内、外均可稳定表达.COX-2基因治疗可抑制裸鼠皮下肿瘤的生长和淋巴管的生成.COX-2基因转染下调血管内皮生长因子-C(VEGF-C)的表达.结论 通过构建靶向COX-2 siRNA真核表达载体可抑制人胃癌裸鼠移植瘤的生长和淋巴管生成,COX-2对抑制胃癌细胞(SGC-7901)治疗有确切效果.  相似文献   

2.
目的:探讨SLP-2siRNA对裸鼠胃癌移植瘤细胞增殖及凋亡的影响.方法:设计合成化学修饰的SLP-2siRNA,将胃癌细胞SGC-7901接种于裸鼠皮下建立裸鼠胃癌移植瘤模型,随机分为转染SLP-2siRNA组、阴性对照组和空白对照组,于肿瘤局部分别多点多次注射化学修饰SLP-2siRNA、阴性对照siRNA及生理盐水.检测3组移植瘤细胞增殖及凋亡状况,RT-PCR及免疫组织化学技术检测移植瘤细胞内SLP-2mRNA及蛋白的表达.结果:与两对照组相比,注射化学修饰的SLP-2siRNA后,裸鼠胃癌移植瘤细胞生长速度减慢、移植瘤体积减小(P=0.009,P=0.003).抑制瘤率分别为26.74%和30.15%,细胞凋亡无明显变化(P>0.05),肿瘤细胞内SLP-2mRNA及蛋白的表达量降低.结论:SLP-2siRNA可抑制人胃癌裸鼠移植瘤的生长,但对细胞凋亡无影响,提示SLP-2基因参与促进胃癌细胞增殖.  相似文献   

3.
目的:探讨重组人生长激素frhGH)对荷人胃癌细胞株SGC-7901裸鼠移植瘤生长及VEGF表达的影响.方法:免疫细胞化学染色法鉴定SGC-7901细胞株GHR表达状态,30只接种皮下移植瘤的裸鼠随机分为:对照组(生理盐水0.2 mL/d).低剂量rhGH组[0.5 U/(kg·d)],高剂量rhGH组[2.5 U/(kg·d)],连续给药14 d,观察并记录裸鼠体质量和肿瘤体积,酶联免疫吸附法测定血清VEGF含量,免疫组织化学法检测胃癌组织中VEGF蛋白表达,RT-PCR检测VEGFmRNA表达.结果:SGC-7901细胞株GHR呈强阳性表达.自rhGH给药第3天起,rhGH给药组与对照组肿瘤体积相差悬殊(P<0.05),且高剂量rhGHVg低剂量rhGH促肿瘤生长效应更加明显(P<0.05),3组间裸鼠体质量差别不明显(P>0.05).裸鼠血清VEGF含量,与对照组和低剂量rhGH组相比,高剂量rhGH组血清中VEGF水平明显升高,差别具有统计学意义(252.94 ng/L±15.32ng/L VS 49.94 ng/L4±5.73 ng/L,167.60 ng/L±9.54 ng/L.均P<0.05).肿瘤组织VEGF蛋白的表达,对照组VEGF表达呈中度阳性;低剂量rhGH组和高剂量rhGH组VEGF表达量高,呈强阳性.肿瘤组织VEGF mRNA表达水平,高剂量rhGH组VEGF相对表达量明显高于对照组和低剂量rhGH组,差别具有统计学意义(0.647±0.0447 vs 0.3234±.0258,0.412±0.035 1.均P<0.05).结论:rhGH能促进GHR阳性表达的SGC-7901移植瘤生长,并促进VEGF表达.  相似文献   

4.
目的观察携带人尾型同源盒转录因子2(Cdx2)基因沉默的重组慢病毒颗粒(Cdx2-RNAi-LV)对人胃癌耐顺铂细胞SGC-7901/DDP裸鼠皮下移植瘤中Survivin和C—myc表达的影响。方法建立人胃癌耐顺铂细胞SGC-7901/DDP裸鼠皮下移植瘤模型,36只裸鼠随机分成3组(n=12):PBS组、LV-RNAi组、Cdx2.RNAi-LV组;各组瘤体内分别注射磷酸盐缓冲液、慢病毒颗粒(0.5×10^8TU/m1)、含Cdx2基因重组慢病毒颗粒(0.5×10^8TU/m1)相应药物100μl,1次/3d,共6次;同时所有裸鼠腹腔注射药物顺铂(25mg/kg),隔天1次,共10次;注射Cdx2-RNAi-LV病毒颗粒第20天后脱颈椎法处死裸鼠,完整切取肿瘤组织,并应用PT-PCR和Westernblot技术检测移植瘤中Survivin和C.myc基因的表达。结果Cdx2.RNAi.LV组、LV.RNAi组和PBS组的细胞均有Survivin、C—myc的mRNA和蛋白的表达,但各组细胞对应的Survivin、C—myc的mRNA和蛋白的表达水平有差别;Cdx2-RNAi—LV组Survivin、C.myc的mRNA和蛋白的表达量较PBS组和LV.RNAi组明显下调(P〈0.05),而PBS组和LV—RNAi组比较差异元统计学意义(P〉0.05)。结论Cdx2基因沉默重组慢病毒颗粒瘤内注射下调人胃癌耐顺铂细胞裸鼠移植瘤Survivin和C-myc表达,可能是Cdx2基因沉默逆转肿瘤的耐药性机制之一。  相似文献   

5.
目的: 探讨CIK细胞对裸鼠人胃癌移植瘤生长的抑制作用.方法: 用淋巴细胞分离液分离外周血单个核细胞, 给予多种细胞因子(rhIFN-γ、CD3mcAb、rhlL-2、rhlL-1), 诱导生成CIK细胞.培养人胃癌细胞株SGC-7901, 接种至40只裸鼠右腋皮下, 10 d后随机分2组, 每组20只, 分别为CIK组和对照组. 连续5 d在接种肿瘤细胞部位处给予CIK细胞和生理盐水注射治疗, 观察CIK细胞对胃癌移植瘤模型的抗肿瘤疗效.结果: CIK组胃癌肿块质量和生存期与对照组相比, 均具有显著性差异(1.21±0.34 g vs2.73±0.45 g, 65.8±6.2 d vs 44.3±4.8 d, 均P<0.01). 裸鼠体内实验表明, CIK细胞能够显著抑制胃癌细胞的生长, 其抑瘤率可达47.6%,明显高于对照组( P<0.01).结论: CIK细胞在裸鼠体内对人胃癌移植瘤有特异性抑瘤作用, 并可以延长裸鼠生存时间.  相似文献   

6.
目的:观察ER-α36分子对人胃癌细胞SGC7901在裸鼠体内生长的影响.方法:利用慢病毒转染技术构建稳定高表达和低表达ERα-36分子的重组人胃癌SGC7901细胞株.实验分为空白对照组(SGC7901-Control)、ER-α36低表达组(SGC7901-Low36)和ER-α36高表达组(SGC7901-High36),每组各3只雄性裸鼠.将上述细胞(5×106个/mL)接种裸鼠皮下,建立裸鼠荷瘤模型,连续观测30d.采用瘤结节体积测量和称质量、瘤组织HE染色及免疫组织化学法检测Ki67指数和E-cadherin蛋白表达等方法,鉴定各组细胞生长的情况.结果:全组实验动物均出现移植瘤.第16天开始,SGC7901-High36组裸鼠肿瘤的体积>SGC7901-Control组裸鼠肿瘤的体积>SGC7901-Low36组裸鼠肿瘤的体积,两两之间有显著性差异(P<0.05).第30天,SGC7901-High36组肿瘤的质量(2.58g±0.014g),明显大于SGC7901-Control组(1.32g±0.0245g)和SGC7901-Low36组(0.471g±0.021g),两两之间有显著性差异(P...  相似文献   

7.
目的探讨靶向CD44的短发夹RNA(shRNA)对人胃癌裸鼠移植瘤生长抑制作用及其机制。方法利用CD44 shRNA细胞及对照细胞株建立裸鼠原位移植瘤及皮下种植瘤模型,监测肿瘤生长变化,采用RT-PCR及免疫组织化学方法检测瘤体内CD44表达的变化,并进一步检测上皮-间质转化(EMT)相关因子表达的变化。结果成功构建了CD44 shRNA转染荷瘤皮下及原位裸鼠模型。与对照shRNA组、空白对照组分别比较,CD44 shRNA组荷瘤裸鼠肿瘤生长速度减慢,皮下种植瘤及原位移植瘤质量减轻,差异均有统计学意义(P均0.01)。RT-PCR结果发现,CD44 shRNA组CD44mRNA表达在皮下种植瘤及原位移植瘤均显著下调,差异均有统计学意义(P均0.01)。CD44 shRNA组细胞EMT相关基因E-cadherin表达增加,N-cadherin、Vimentin表达降低。结论 CD44 shRNA可以有效抑制人胃癌SGC7901细胞裸鼠移植瘤生长,并下调CD44的表达水平,这可能与CD44基因参与EMT相关。  相似文献   

8.
目的:研究siRNA沉默糖体蛋白L31(ribosomal protein L31,RPL31)对人胰腺癌BxPC-3细胞裸鼠皮下移植瘤的抑制作用,探讨RPL31基因在胰腺癌中可能的作用机制.方法:设计合成靶向人RPL31基因的siRNA及阴性对照siRNA;建立人胰腺癌BxPC-3细胞的Balb/c裸鼠皮下移植瘤模型,按照移植瘤体积随机化分为3组:溶剂对照组、阴性对照组及RPL31-siRNA干预组;使用RNAi-Mate转染试剂将RPL31-siRNA进行移植瘤瘤内注射,观察各组裸鼠体内瘤体生长速度,绘制肿瘤生长曲线;采用实时定量PCR及Western blot的方法检测移植瘤组织RPL31基因的表达;免疫组织化学法(immunohistochemistry,IHC)检测裸鼠皮下移植瘤Ki-67及CD31的表达;原位末端标记技术(TUNEL)检测移植瘤组织的细胞凋亡.结果:与溶剂对照组和阴性对照组相比,RPL31-siRNA注射组裸鼠皮下移植瘤生长缓慢,移植瘤体积明显缩小,差异具有统计学意义(P<0.05);移植瘤组织中RPL31基因的mRNA水平和蛋白水平表达下调;另外,RPL31-siRNA注射组裸鼠移植瘤中Ki-67表达下调(55.78%±4.63%、51.37%±5.05%vs11.08%±1.31%),CD31的表达下调(56.53%±6.03%、44.84%±5.24%vs9.67%±1.39%);RPL31-siRNA注射组裸鼠移植瘤细胞凋亡增加(2.92%±0.54%、3.85%±0.87%vs39.58%±4.02%).结论:RPL31-siRNA可以下调胰腺癌BxPC-3细胞裸鼠皮下移植瘤中RPL31基因的表达,抑制移植瘤的生长,并且还可以抑制移植瘤中Ki-67及CD31的表达,诱导移植瘤细胞的凋亡.以RPL31为靶点的基因治疗有潜在临床应用前景.  相似文献   

9.
目的:研究转染GKLF基因对人胃癌SGC-7901细胞裸鼠皮下移植瘤的作用,探讨GKLF在胃癌中可能的作用机制.方法:将外源性重组真核质粒pcDNA3.1-GKLF转染到人胃癌细胞株SGC-7901内,经G418筛选并建立高表达GKLF的稳定转染细胞株.稳定表达该基因的细胞为SGC7901-peDNA3.1-GKLF组...  相似文献   

10.
目的: 研究携带Slug-siRNA的rAAV对裸鼠体内胰腺癌的作用.方法: 建立人胰腺癌裸鼠皮下移植瘤模型,2wk后随机将建模成功的裸鼠分为3组,每组6只. 构建携带Slug-siRNA的rAAV载体,采用瘤体内多点注射的方法,阴性对照组裸鼠按1×109 puf(50 μL)标准注射rAAV-EGFP,空白对照组裸鼠注射等量生理盐水,实验组裸鼠按1×109 puf(50 μL)标准注射rAAV2-EGFP-slugsiRNA,只注射1次. 观察裸鼠的一般情况,摄食,活动能力,每周用电子天平秤体质量,绘制裸鼠生长曲线. 治疗6 wk后二氧化碳吸入法处死裸鼠,切取肿瘤称质量;免疫组织化学SP法检测slug蛋白的表达,TUNEL检测皮下移植瘤细胞凋亡,透射电镜检测细胞超微结构.结果: 3组裸鼠分别接受不同的处理后,在开始的2 wk皮下移植瘤的生长无明显差别,2 wk以后,实验组裸鼠皮下移植瘤的体积增长明显滞后于阴性对照组和空白对照组,差异有统计学意义( P<0.05). 治疗6 wk后,实验组裸鼠皮下移植瘤的质量明显轻于阴性对照组和空白对照组差异有统计学意义(3.26±0.48 g vs7.56±1.25 g,7.50±1.23 g,均P<0.05). 实验组裸鼠皮下移植瘤的AI值明显高于阴性对照组和空白对照组,差异有统计学意义(0.27±0.06vs 0.024±0.01,0.025±0.01,均P<0.05);实验组的抑瘤率明显高于阴性对照组,差异有统计学差异(71.4% vs 0.04%,P<0.01). 透射电镜下,实验组肿瘤细胞可见细胞器结构模糊,核固缩,染色质边集等现象. 免疫组织化学检测示实验组Slug表达明显减少.结论: Slug基因被有效沉默,Slug基因沉默后促进细胞凋亡,抑制胰腺癌实体瘤增殖和生长.  相似文献   

11.
INTRODUCTION Arsenic has been used since ancient times as a therapeutic agent. However, until recently its use in modern medicine has been restricted to the treatment of a limited number of parastic infections. Since the early 1990s, arsenic trioxide (As2…  相似文献   

12.
目的 探讨外源性胃肠富集Krüppel样因子(GKLF)基因转染对人胃癌细胞株SGC-7901在体内外的抗肿瘤效应.方法 荧光实时定量PCR和Western印迹法检测GKLF基因转染前后人胃癌细胞株SGC-7901中GKLF mRNA和蛋白的表达.应用四甲基偶氮唑盐(MTT)法、流式细胞技术、克隆形成实验和细胞侵袭实验分别检测GKLF基因转染后SGC-7901细胞增殖和侵袭力的变化.观察裸鼠移植瘤生长情况和应用免疫组织化学法检测移植瘤组织中微血管密度(MVD).结果 GKLF基因转染后,SGC7901-pcDNA3.1-GKLF组中GKLF mRNA(0.1216±0.0061)和蛋白(1.0547±0.0172)的表达明显高于SGC-7901组[分别为(0.0029±0.0012)和(0.6240±0.0177)]和SGC7901-pcDNA3.1组[分别为(0.0037±0.0013)和(0.5627±0.0510)],P<0.05.与SGC-7901组和SGC7901-pcDNA 3.1组相比,从48 h开始,SGC7901-pcDNA 3.1-GKLF组细胞生长速度减慢、细胞出现G0/G1期部分阻滞、克隆形成率低、细胞侵袭力明显减弱(P值均<0.05).SGC7901-pcDNA3.1-GKLF组皮下移植瘤生长速度减慢、瘤重轻、MVD低(P值均<0.05).结论 GKLF基因转染可导致人胃癌细胞株SGC-7901的增殖活性和侵袭力降低,抑制裸鼠移植瘤生长和血管生成.
Abstract:
Objective To investigate the antitumour effects of transfected gut-enriched Krüppellike factor(GKLF) on human gastric carcinoma cell line SGC-7901 in vitro and in vivo. Methods The expression of GKLF mRNA and protein in human gastric carcinoma cell line SGC-7901 were detected before and after transfection by real-time fluorescence quantitative PCR and Western blot,respectively. Proliferation and invasion in SGC-7901 were measured respectively by MTT assay, flow cytometry, colony formation assay and cell invasion assay after transfected with GKLF. The growth of xenograft was observed, the microvessel density(MVD) of xenograft tissue was determined by immunohistochemistry. Results The GKLF mRNA and protein in SGC-7901 were overexpressed after transfected with GKLF(P<0.05). The proliferative speed of SGC7901-pcDNA3.1-GKLF group was markedly lower than that of SGC-7901 and SGC7901-pcDNA3.1 groups (P<0.05). Transfected with GKLF caused part of the G0/G1 arrest, decreased clone formation rate and the invasion ability (P<0.05). The growth speed of xenograft in SGC7901-pcDNA3.1-GKLF group was lower, the weight and MVD of xenograft tissue in SGC7901-pcDNA3. 1-GKLF group were less (P< 0. 05).Conclusion Transfected with GKLF maysuppress proliferation and invasion in human gastric carcinoma cell line SGC-7901, inhibit the growth and the angiogenesis of xenograft in nude mice.  相似文献   

13.
AIM:To establish a gastric cancer nude-mouse model with improved orthotopic implantation and investigate its biological characteristics at different time points.METHODS:Human gastric cancer SGC-7901 cell suspensions were injected subcutaneously into a nude mouse to develop solid tumors,and the tumor tissue pieces were implanted under the serous coat.The nude mice were then euthanized in group every two weeks to observe the primary tumor growth and metastases.RESULTS:Within 2-4 wk,there were no obvious chang...  相似文献   

14.
AIM: To develop orthotopic gastric cancer mouse models from different cell lines and characterize the tumor features to assist further in preclinical trials and clinical treatment strategies.METHODS: Human gastric cancer SGC-7901 and BGC-823 cell suspensions were injected subcutaneously into nude mice to develop solid tumors, and tumor tissue pieces were then implanted under the serous coat of the stomach. An autopsy was performed on all animals of the SGC-7901 and BGC-823 models to observe the primary tumor growth and metastases using pathological and immunohistochemical methods.RESULTS: Both models showed large tumors in situ resulting in pressure and infiltration of the adjacent organs. The gastric cavity became smaller, along with stenosis of the cardia or pylorus. There were biological and statistical differences between the two models. The metastasis rate in involved organs (lymph nodes, kidney, spleen, testis) was significantly higher in the BGC-823 model compared to the SGC-7901 model (P < 0.05 or P < 0.01). The median survival of the BGC-823 model was shorter than that of SGC-7901 (23 d vs 84 d, P < 0.05). Histopathologically, the primary tumor and metastatic lesions of the two models showed obvious atypia and mucus in the cytoplasm. Compared with the SGC-7901 model, BGC-823 appeared more poorly differentiated (absence of adenoid structure), had a smaller volume, and richer capillary structure. Immunohistochemical staining revealed cytokeratin 20 and epithelial membrane antigen expression was positive in the SGC-7901 tumors, while negative in BGC-823 ones.CONCLUSION: Models using the SGC-7901 and BGC-823 cell lines were established which could function in gastric cancer research on carcinogenesis mechanism and drug discovery. The two models showed different tumor behavior and the latter was more malignant than the former.  相似文献   

15.
AIM To study the effects of ATRA on experimental liver metastasis of gastric cancer cells.METHODS MGc80-3 and SGC-7901 cells were injectied into spleen subcapsule of nude mice, who weresubsequently administrated with ATRA every other day. Food-intake and body weight of mice were measuredweekly. After six weeks, the nude mice were executed, tumors in spleen and liver were examinedpathologically, microtumor vessel density (MVD) was accounted by immunohistochemical method and serumCEA was measured by radioimmunoassay.RESULTS Nude mice administrated with ATRA, the growth of spleen tumor and its metastatic ability toliver were inhibited, the metastatic rate was decreased by 33.3% (MGc80-3) and 50.0% (SGC-7901). SpleenMVD and liver MVD were reduced by 28.6% and 22.9% (MGc80-3), 23.7% and 37.6% (SGC-7901),respectively. The serum CEA was lowered by 43.4% (MGc80-3).CONCLUSION ATRA can effectively inhibit the experimental liver metastasis of gastric cancer cells,which is relavant with the decrease of MVD and CEA.  相似文献   

16.
AIM: To study the effect of type 1 Na^+/H^+ exchanger (NHE1 ) antisense human gene transfection on the biological behavior of gastric carcinoma cell line SGC-7901. METHODS: Antisense NHE1 eukaryotic expression on vector pcDNA3.1 was constructed by recombinant DNA technique and transfected into gastric carcinoma cell line SGC-7901 with DOTAP liposome transfection method. Morphological changes of cells were observed with optic and electron microscopes. Changes in cell proliferative capacity, apoptosis, intracellular pH (pHi), cell cycle, clone formation in two-layer soft agar, and tumorigenicity in nude mice were examined. RESULTS: Antisense eukaryotic expressing vectors were successfully constructed and transfected into SGC-7901. The transfectant obtained named 7901 -antisense (7901-AS) stablely produced antisense NHE1. There was a significant difference between the pHi of 7901-AS cells (6.77 ± 0.05) and that of 7901-zeo cells and SGC-7901 cells (7.24 ± 0.03 and 7.26 ± 0.03, P 〈 0.01). Compared with SGC-7901 and 7901-zeo cells, 7901-AS cells mostly showed cell proliferation inhibition, G1/G0 phase arrest, increased cell apoptotic rate, recovery of contact inhibition, and density contact. The tumorigenicity in nude mice and cloning efficiency in the two-layer soft agar were clearly inhibited. CONCLUSION: NHE1 antisense gene significantly restrains the malignant behavior of human gastric carcinoma cells, suppresses cell growth and induces cell apoptosis, and partially reverses the malignant phenotypes of SGC-7901 . These results suggest a potential role for human tumor gene therapy.  相似文献   

17.
AIM: To study the inhibitory effect of baculovirusmediated normal epithelial cell specific-1 (NES1) gene therapy on gastric cancer (GC) in vitro and in vivo. METHODS: We first constructed recombinant baculovirus vectors and then transfected them into gastric cancer cells (SGC-7901). Efficiency of the baculovirus for gene transfer into SGC-7901 cells and cell growth curves were detected by fluorescence microscopy, Western blot and 3-(4,5-dimethylthiazol- 2-yl)-2,5-diphenyltetrazolium bromide (MTT) assay in vitro, respectively. The therapeutic effect of this gene therapy on GC was confirmed in xenografted nude mice. Tumor growth was determined by tumor volume, and expression of NES1 in tumor was analyzed by immunohistochemistry. RESULTS: Baculovirus vectors were successfully transfected into SGC-7901 cells. SGC-7901 cells transfected with the NES1 gene inhibited cell growth. In the Bac-NES1 treated group, tumor growth was significantly reduced with a high level of NES1 expression CONCLUSION: Baculovirus-mediated NES1 gene can be used in gene therapy for GC.  相似文献   

18.
温郁金对人胃癌裸鼠移植瘤生长和环氧合酶-2表达的影响   总被引:1,自引:0,他引:1  
背景:温郁金为常用传统中药材,研究发现其组分具有抗癌作用。目的:研究温郁金对人胃癌裸鼠移植瘤生长和环氧合酶-2(COX-2)表达的影响,探讨其抑制胃癌的作用机制。方法:将人胃癌细胞系SGC-7901种植于裸鼠皮下,建立胃癌移植瘤模型。待瘤体长至约2mm时,12只荷瘤裸鼠随机分为治疗组和对照组,分别予温郁金提取液0.3ml和等量0.9%NaCl溶液灌胃,每日2次,连续7周。每周测量一次瘤体大小,7周后处死裸鼠,测定肿瘤重量。以免疫组化Elivision^TM plus法检测肿瘤组织COX-2的表达。结果:治疗组裸鼠移植瘤体积和重量均显著低于对照组.抑瘤率为42.5%;肿瘤组织COX-2阳性染色强度和阳性细胞百分率亦显著低于对照组。结论:温郁金对人胃癌裸鼠移植瘤的生长具有明显抑制作用,抑制肿瘤组织中COX-2的表达可能是其作用机制。  相似文献   

设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司    京ICP备09084417号-23

京公网安备 11010802026262号